Menlo Park, United States
Synthekine, founded in 2018, is a biotechnology company headquartered in the United States, focused on engineered cytokine therapeutics for cancer and autoimmune disorders. By leveraging immunological insights and targeted protein engineering, Synthekine aims to discover and develop groundbreaking treatments. The company's innovative approach centers on harnessing cytokine partial agonism and immunological specificity to design safe and effective therapeutics.
The disruptive potential of Synthekine’s treatments has been substantiated by promising efficacy and tolerability in preclinical studies. As it continues to develop additional cytokine partial agonists, Synthekine remains committed to selectively modulating critical immune system pathways.
Having recently secured a $100.00M Series C investment from The Column Group on 01 January 2023, Synthekine is well-positioned to advance its lead programs and explore emerging opportunities within the Health and Wellness and Life Sciences sectors.
Electra Therapeutics